Aptevo Therapeutics achieves major breakthrough with mipletamig in acute myeloid leukemia
Aptevo Therapeutics has unveiled remarkable findings from Cohort 1 of its RAINIER clinical trial for mipletamig, a bispecific antibody aimed at tackling acute myeloid leukemia ... Read More
OncoVerity accelerates AML treatment with Series A extension
OncoVerity, a leader in integrating bioinformatics with oncology drug development, has closed a Series A extension financing round, bolstered by its key investors, argenx and ... Read More
AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study
AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus VENCLEXTA/VENCLYXTO (venetoclax) (I+V) has met ... Read More
Tolero Pharmaceuticals and AbbVie collaborate to advance AML treatment
Tolero Pharmaceuticals has entered into a clinical research collaboration with AbbVie to explore the potential of combining their respective drugs, alvocidib and venetoclax, for the ... Read More